Evidence map›Paper›PMID 27465541›Full record

ArticleStem cell research & therapy2016

A reduction in CD90 (THY-1) expression results in increased differentiation of mesenchymal stromal cells.

Daniela A Moraes, Tatiana T Sibov, Lorena F Pavon, Paula Q Alvim, Raphael S Bonadio, Jaqueline R Da Silva, Aline Pic-Taylor, Orlando A Toledo, Luciana C Marti, Ricardo B Azevedo and 1 more

Open access · goldAbstract read
In one paragraph

Article in Stem cell research & therapy, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 117 papers.

0numbers the graph read from it
0cells of the map it votes in
117citing papers in PubMed
9.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

117 citing papers in PubMed, 211 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Mutanobactin-D, aInternational journal of molecular sciences · 2025
    Article
  18. Article
  19. Article
  20. Article

57 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Daniela A MoraesDepartamento de Genética e Morfologia, Universidade de Brasília, Brasília, DF, Brazil.
Tatiana T SibovDepartamento de Neurologia e Neurocirurgia, Universidade Federal de São Paulo, São Paulo, SP, Brazil.
Lorena F PavonDepartamento de Neurologia e Neurocirurgia, Universidade Federal de São Paulo, São Paulo, SP, Brazil.
Paula Q AlvimDepartamento de Genética e Morfologia, Universidade de Brasília, Brasília, DF, Brazil.
Raphael S BonadioDepartamento de Genética e Morfologia, Universidade de Brasília, Brasília, DF, Brazil.
Jaqueline R Da SilvaDepartamento de Genética e Morfologia, Universidade de Brasília, Brasília, DF, Brazil.
Aline Pic-TaylorDepartamento de Genética e Morfologia, Universidade de Brasília, Brasília, DF, Brazil.
Orlando A ToledoDepartamento de Ciências da Saúde, Universidade de Brasília, Brasília, DF, Brazil.
Luciana C MartiHospital Israelita Albert Einstein, Instituto de Ensino e Pesquisa - Centro de Pesquisa Experimental São Paulo, São Paulo, SP, Brazil.
Ricardo B AzevedoDepartamento de Genética e Morfologia, Universidade de Brasília, Brasília, DF, Brazil.
Daniela M OliveiraDepartamento de Genética e Morfologia, Universidade de Brasília, Brasília, DF, Brazil. dmoliveira@unb.br.
Universidade de Brasília · BRUniversidade Federal de São Paulo · BRInsper · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMesenchymal stromal cells (MSCs) are multipotent progenitor cells used in several cell therapies. MSCs are characterized by the expression of CD73, CD90, and CD105 cell markers, and the absence of CD34, CD45, CD11a, CD19, and HLA-DR cell markers. CD90 is a glycoprotein present in the MSC membranes and also in adult cells and cancer stem cells. The role of CD90 in MSCs remains unknown. Here, we sought to analyse the role that CD90 plays in the characteristic properties of in vitro expanded human MSCs.

methodsWe investigated the function of CD90 with regard to morphology, proliferation rate, suppression of T-cell proliferation, and osteogenic/adipogenic differentiation of MSCs by reducing the expression of this marker using CD90-target small hairpin RNA lentiviral vectors.

resultsThe present study shows that a reduction in CD90 expression enhances the osteogenic and adipogenic differentiation of MSCs in vitro and, unexpectedly, causes a decrease in CD44 and CD166 expression.

conclusionOur study suggests that CD90 controls the differentiation of MSCs by acting as an obstacle in the pathway of differentiation commitment. This may be overcome in the presence of the correct differentiation stimuli, supporting the idea that CD90 level manipulation may lead to more efficient differentiation rates in vitro.

Indexed as

Gene SilencingActivated-Leukocyte Cell Adhesion MoleculeAdipocytesAdipose TissueAmniotic FluidAntigens, CDCell Adhesion Molecules, NeuronalCell DifferentiationCell ProliferationDental PulpFetal ProteinsHumansHyaluronan ReceptorsImmunophenotypingLentivirusMesenchymal Stem CellsActivated-Leukocyte Cell Adhesion MoleculeALCAM protein, humanAntigens, CDCD44 protein, humanCell Adhesion Molecules, NeuronalFetal ProteinsHyaluronan ReceptorsRNA, Small InterferingThy-1 AntigensCD90DifferentiationFibroblastMesenchymal stem cellsMesenchymal stromal cellsThy-1

Identifiers

PMID27465541
PMCPMC4964048
OpenAlexW2506259081

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.